Loading
A phase 1/2 trial of Glecirasib, Cetuximab in colorectal cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting.
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation is a phase 1/2 interventional study registered as NCT05194995 by Allist Pharmaceuticals, Inc., with 48 participants enrolled, started 2022-02-17 and due to reach its primary completion in 2025-04-30. Interventions recorded: JAB-21822, Cetuximab. Conditions listed: Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer. No results are recorded here; the registry entry is the source.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS & RAS inhibitors, Small-molecule kinase inhibitors.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS G12C-mutant colorectal cancer, KRAS & RAS inhibitors.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS & RAS inhibitors, Small-molecule kinase inhibitors.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS & RAS inhibitors, Small-molecule kinase inhibitors.
Shares KRAS G12C-mutant colorectal cancer, Cetuximab, Monoclonal antibodies, Colorectal cancer.
Shares KRAS G12C-mutant colorectal cancer, KRAS & RAS inhibitors, Cetuximab, Monoclonal antibodies.
Shares KRAS G12C-mutant colorectal cancer, KRAS & RAS inhibitors, Monoclonal antibodies, Colorectal cancer.